These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15477582)

  • 1. A novel formulation of selegiline for the treatment of Parkinson's disease.
    Tetrud JW; Koller WC
    Neurology; 2004 Oct; 63(7 Suppl 2):S2-6. PubMed ID: 15477582
    [No Abstract]   [Full Text] [Related]  

  • 2. Development and evaluation of buccoadhesive tablet for selegiline hydrochloride based on thiolated polycarbophil.
    Wasnik MN; Godse RD; Nair HA
    Drug Dev Ind Pharm; 2014 May; 40(5):632-8. PubMed ID: 24517570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selegiline for Parkinson's disease.
    Calesnick B
    Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl).
    Waitzinger J; Ludwig G; Pabst G; Michaelis K; Reh C
    Int J Clin Pharmacol Ther; 1996 Oct; 34(10):427-32. PubMed ID: 8897080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (-)Deprenyl (selegiline) in Parkinson's disease: a pharmacologist's comment.
    Knoll J
    Biomed Pharmacother; 1996; 50(6-7):315-7. PubMed ID: 8952875
    [No Abstract]   [Full Text] [Related]  

  • 7. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
    Jenner P
    Neurology; 2004 Oct; 63(7 Suppl 2):S13-22. PubMed ID: 15477581
    [No Abstract]   [Full Text] [Related]  

  • 9. [Optimization of the treatment of Parkinson's disease using dopamine agonists].
    Rinne UK
    Arch Neurobiol (Madr); 1991; 54(6):282-7. PubMed ID: 1687430
    [No Abstract]   [Full Text] [Related]  

  • 10. Is 10 milligrams selegiline essential as an adjunct therapy for the symptomatic treatment of Parkinson's disease?
    Mahmood I
    Ther Drug Monit; 1998 Dec; 20(6):717-21. PubMed ID: 9853994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials of neuroprotection for Parkinson's disease.
    LeWitt PA
    Neurology; 2004 Oct; 63(7 Suppl 2):S23-31. PubMed ID: 15477583
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of platelet monoamine oxidase type B by selegiline.
    Heinonen EH; Anttila MI; Nyman LM; Pyykkö KA; Vuorinen JA; Lammintausta RA
    J Clin Pharmacol; 1997 Jul; 37(7):597-601. PubMed ID: 9243352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
    Clarke A; Johnson ES; Mallard N; Corn TH; Johnston A; Boyce M; Warrington S; MacMahon DG
    J Neural Transm (Vienna); 2003 Nov; 110(11):1257-71. PubMed ID: 14628190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotection by selegiline and other MAO inhibitors.
    Stern G
    J Neural Transm Suppl; 1998; 52():99-107. PubMed ID: 9564613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selegiline orally disintegrating tablets for the treatment of Parkinson's disease.
    Lew MF
    Expert Rev Neurother; 2005 Nov; 5(6):705-12. PubMed ID: 16274328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease.
    Tábi T; Szökő E; Vécsei L; Magyar K
    Expert Opin Drug Metab Toxicol; 2013 May; 9(5):629-36. PubMed ID: 23506388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
    Andreu N; Damase-Michel C; Senard JM; Rascol O; Montastruc JL
    Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy for patients with early-stage Parkinson's disease].
    Tanaka M; Okamoto K
    Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1426-31. PubMed ID: 13677890
    [No Abstract]   [Full Text] [Related]  

  • 20. MAO-B inhibitor know-how: back to the pharm.
    Lewitt PA
    Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.